Hippocratic AI Secures $126M Series C Funding, Expands Patient-Facing AI Agents

Hippocratic AI, a leading healthcare technology startup, has announced a significant $126 million Series C funding round, bringing its total funding to $404 million and boosting its valuation to $3.5 billion. The investment, led by Avenir Growth, signals growing confidence in the company's patient-facing AI agents and its commitment to safe, scalable healthcare solutions.

Rapid Growth and Industry Partnerships

Since its launch in 2024, Hippocratic AI has experienced remarkable growth, forging partnerships with over 50 large health systems, payers, and pharmaceutical clients. The company has developed 1,000 use cases for its AI agents, which have completed more than 115 million clinical patient interactions without safety issues.

Notable adopters of Hippocratic AI's technology include Cleveland Clinic, Northwestern Medicine, Ochsner Health, and University Hospitals, among others. The company has also expanded internationally, now operating in six countries.

Safety-First Approach to AI in Healthcare

Hippocratic AI distinguishes itself through a rigorous focus on safety and reliability. The company has implemented a multi-step framework to certify its product's safety, including:

• A constellation architecture featuring nearly 30 large language models (LLMs) supporting and supervising the main model
• Extensive output testing and validation by over 7,000 U.S.-licensed clinicians
• Real-time escalation protocols based on validated nurse guidelines
• Development of a proprietary speech recognition system with a 6% word error rate

Munjal Shah, co-founder and CEO of Hippocratic AI, emphasized the company's commitment to safety: "Our main thesis with building a product was ensuring that it could do these patient-facing conversations safely."

Expanding Applications and Future Growth

The new funding will fuel Hippocratic AI's product development and international expansion. The company's AI agents currently handle a wide range of tasks, including:

• Patient intake screening
• Annual wellness visit outreach
• Chronic care management
• Post-surgical and post-discharge follow-up
• Medication adherence and cancer screenings

For payers and pharmaceutical companies, the AI agents assist with eligibility confirmations, case management, clinical trial pre-screening, and patient education.

Shah also hinted at potential M&A opportunities, stating, "We realized there's some good opportunities in the market to continue to expand the offering and continue to take this position and scale it."

As Hippocratic AI continues to grow and innovate, it remains committed to its core mission of providing safe, scalable AI solutions that address healthcare staffing shortages and improve patient care without compromising on safety or empathy.